| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.489 | 0.013 | 0.489 | Vasodilator | 0.273 0.058 DBMET00850 | ||
| 0.414 | 0.012 | 0.414 | Non-steroidal antiinflammatory agent | 0.18 0.088 DBMET00850 | ||
| 0.485 | 0.094 | 0.485 | Antiinflammatory | |||
| 0.397 | 0.046 | 0.397 | Caspase 3 stimulant | |||
| 0.366 | 0.022 | 0.366 | RNA-directed DNA polymerase inhibitor | 0.223 0.071 DBMET00850 | ||
| 0.394 | 0.08 | 0.394 | Antibacterial | |||
| 0.292 | 0.004 | 0.292 | CYP2A6 inhibitor | 0.121 0.026 DBMET00850 | ||
| 0.289 | 0.019 | 0.289 | Monophenol monooxygenase inhibitor | |||
| 0.345 | 0.089 | 0.345 | GABA C receptor rho-3 antagonist | 0.212 0.193 DBMET00850 | ||
| 0.268 | 0.013 | 0.268 | Cell wall synthesis inhibitor | 0.114 0.109 DBMET00850 | ||
| 0.253 | 0.002 | 0.253 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.136 0.004 DBMET00850 | ||
| 0.256 | 0.02 | 0.256 | Cyclooxygenase 1 inhibitor | |||
| 0.3 | 0.094 | 0.3 | Transcription factor NF kappa B inhibitor | |||
| 0.243 | 0.041 | 0.243 | I kappa B kinase epsilon inhibitor | |||
| 0.218 | 0.035 | 0.218 | Cyclooxygenase inhibitor | |||
| 0.227 | 0.044 | 0.227 | Anticoagulant | |||
| 0.227 | 0.052 | 0.227 | Nitric-oxide synthase stimulant | 0.199 0.09 DBMET00850 | ||
| 0.23 | 0.057 | 0.23 | MAP kinase kinase 3 inhibitor | 0.221 0.072 DBMET00850 | ||
| 0.183 | 0.013 | 0.183 | Nitric-oxide synthase inhibitor | 0.113 0.043 DBMET00850 | ||
| 0.183 | 0.014 | 0.183 | Porphobilinogen synthase inhibitor | 0.119 0.029 DBMET00850 | ||
| 0.24 | 0.081 | 0.24 | Superoxide dismutase inhibitor | 0.168 0.158 DBMET00850 | ||
| 0.214 | 0.056 | 0.214 | Peroxidase inhibitor | |||
| 0.251 | 0.095 | 0.251 | Insulysin inhibitor | 0.189 0.174 DBMET00850 | ||
| 0.246 | 0.091 | 0.246 | 5 Hydroxytryptamine release stimulant | 0.195 0.125 DBMET00850 | ||
| 0.157 | 0.013 | 0.157 | HIV-1 reverse transcriptase inhibitor | |||
| 0.2 | 0.061 | 0.2 | Dual specificity phosphatase 3 inhibitor | |||
| 0.178 | 0.039 | 0.178 | Cyclooxygenase 2 inhibitor | |||
| 0.148 | 0.009 | 0.148 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.172 | 0.036 | 0.172 | Aldehyde dehydrogenase inhibitor | 0.114 0.078 DBMET00850 | ||
| 0.158 | 0.023 | 0.158 | Gastric antisecretory | |||
| 0.19 | 0.056 | 0.19 | Heat shock protein 90 alpha antagonist | |||
| 0.233 | 0.1 | 0.233 | Gastrin inhibitor | |||
| 0.225 | 0.103 | 0.225 | Spasmolytic | |||
| 0.194 | 0.073 | 0.194 | 5 Hydroxytryptamine 3E antagonist | 0.191 0.079 DBMET00850 | ||
| 0.16 | 0.04 | 0.16 | Cyclooxygenase 3 inhibitor | |||
| 0.17 | 0.05 | 0.17 | GABA C receptor rho-2 antagonist | |||
| 0.284 | 0.164 | 0.284 | Transcription factor inhibitor | |||
| 0.294 | 0.176 | 0.294 | Apoptosis agonist | |||
| 0.144 | 0.036 | 0.144 | GABA C receptor agonist | 0.111 0.056 DBMET00850 | ||
| 0.136 | 0.029 | 0.136 | GABA C receptor rho-1 antagonist | 0.091 0.076 DBMET00850 | ||
| 0.125 | 0.023 | 0.125 | Inducible nitric-oxide synthase inhibitor | 0.086 0.052 DBMET00850 | ||
| 0.128 | 0.03 | 0.128 | Alcohol dehydrogenase inhibitor | 0.085 0.071 DBMET00850 | ||
| 0.134 | 0.038 | 0.134 | Bronchodilator | |||
| 0.303 | 0.209 | 0.303 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.118 | 0.025 | 0.118 | Alpha 2d adrenoreceptor antagonist | 0.107 0.038 DBMET00850 | ||
| 0.104 | 0.016 | 0.104 | Secretase beta inhibitor | |||
| 0.13 | 0.043 | 0.13 | GABA C receptor antagonist | 0.1 0.078 DBMET00850 | ||
| 0.164 | 0.08 | 0.164 | Dual specificity phosphatase inhibitor | |||
| 0.091 | 0.009 | 0.091 | Epithelial sodium channel blocker | |||
| 0.083 | 0.005 | 0.083 | Endothelial nitric-oxide synthase inhibitor | 0.036 0.016 DBMET00850 | ||
| 0.131 | 0.054 | 0.131 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.079 | 0.005 | 0.079 | Dopamine beta hydroxylase inhibitor | 0.046 0.041 DBMET00850 | ||
| 0.208 | 0.136 | 0.208 | 5 Hydroxytryptamine uptake stimulant | 0.191 0.17 DBMET00850 | ||
| 0.149 | 0.076 | 0.149 | Heat shock protein 90 antagonist | |||
| 0.144 | 0.072 | 0.144 | Lipid peroxidase inhibitor | |||
| 0.098 | 0.036 | 0.098 | Histamine H2 receptor antagonist | |||
| 0.116 | 0.059 | 0.116 | 5 Hydroxytryptamine 3A agonist | |||
| 0.067 | 0.011 | 0.067 | Histamine H2 receptor agonist | 0.051 0.021 DBMET00850 | ||
| 0.112 | 0.06 | 0.112 | Ferrochelatase inhibitor | |||
| 0.112 | 0.061 | 0.112 | Acetylcholine release stimulant | |||
| 0.059 | 0.009 | 0.059 | Histamine H1 receptor agonist | 0.051 0.017 DBMET00850 | ||
| 0.075 | 0.026 | 0.075 | Alcohol oxidase inhibitor | |||
| 0.194 | 0.147 | 0.194 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.09 | 0.049 | 0.09 | I kappa B kinase inhibitor | |||
| 0.055 | 0.018 | 0.055 | Geranyltranstransferase inhibitor | 0.042 0.034 DBMET00850 | ||
| 0.165 | 0.129 | 0.165 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.051 | 0.016 | 0.051 | Angiotensin AT1 receptor antagonist | |||
| 0.134 | 0.101 | 0.134 | Heat shock protein 70 antagonist | |||
| 0.059 | 0.028 | 0.059 | Histamine agonist | |||
| 0.136 | 0.104 | 0.136 | CF transmembrane conductance regulator agonist | |||
| 0.053 | 0.022 | 0.053 | Cytokine production stimulant | 0.047 0.038 DBMET00850 | ||
| 0.161 | 0.133 | 0.161 | Platelet antagonist | |||
| 0.079 | 0.051 | 0.079 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.071 | 0.045 | 0.071 | Phenylalanine 4-hydroxylase inhibitor | |||
| 0.252 | 0.226 | 0.252 | 5 Hydroxytryptamine release inhibitor | |||
| 0.129 | 0.103 | 0.129 | Adenylate cyclase stimulant | |||
| 0.05 | 0.025 | 0.05 | Sphingosine 1-phosphate receptor agonist | |||
| 0.055 | 0.031 | 0.055 | Aconitate hydratase inhibitor | |||
| 0.038 | 0.017 | 0.038 | Angiotensin II receptor antagonist | |||
| 0.091 | 0.07 | 0.091 | Creatine kinase inhibitor | |||
| 0.081 | 0.061 | 0.081 | Transforming growth factor beta 3 antagonist | |||
| 0.057 | 0.038 | 0.057 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | |||
| 0.06 | 0.04 | 0.06 | Carbonic anhydrase stimulant | 0.057 0.044 DBMET00850 | ||
| 0.04 | 0.022 | 0.04 | Glutamate (mGluR8) agonist | 0.035 0.033 DBMET00850 | ||
| 0.068 | 0.05 | 0.068 | Transforming growth factor antagonist | |||
| 0.04 | 0.024 | 0.04 | Diamine oxidase inhibitor | |||
| 0.04 | 0.025 | 0.04 | Retinoic acid alpha receptor agonist | |||
| 0.054 | 0.041 | 0.054 | Immunoglobulin Fc receptor antagonist | |||
| 0.074 | 0.06 | 0.074 | Macrophage migration inhibitory factor inhibitor | |||
| 0.061 | 0.047 | 0.061 | Histone deacetylase SIRT3 inhibitor | |||
| 0.048 | 0.036 | 0.048 | Transforming growth factor beta 1 antagonist | |||
| 0.192 | 0.18 | 0.192 | Thioredoxin glutathione reductase inhibitor | |||
| 0.05 | 0.04 | 0.05 | Ribonucleoside-diphosphate reductase inhibitor | |||
| 0.043 | 0.034 | 0.043 | Fructose-1,6-bisphosphatase inhibitor | |||
| 0.078 | 0.07 | 0.078 | Histamine N-methyltransferase inhibitor | |||
| 0.019 | 0.011 | 0.019 | Alpha 2b adrenoreceptor agonist | |||
| 0.067 | 0.059 | 0.067 | Glutamate decarboxylase inhibitor | |||
| 0.049 | 0.043 | 0.049 | Ribonucleotide reductase inhibitor | |||
| 0.043 | 0.038 | 0.043 | Adenosine deaminase inhibitor | |||
| 0.017 | 0.014 | 0.017 | Complement factor D inhibitor | |||
| 0.207 | 0.204 | 0.207 | Calcium channel activator | |||
| 0.009 | 0.292 | 0.354 | Aldose reductase inhibitor | 0.354 0.004 DBMET00850 | DBMET00850 | |
| 0.052 | 0.417 | 0.225 | Hepatoprotectant | 0.225 0.052 DBMET00850 | DBMET00850 | |
| 0.044 | 0.66 | 0.558 | Cyclophilin D inhibitor | 0.558 0.036 DBMET00850 | DBMET00850 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |